Athira Pharma, Inc. (ATHA)Â
NASDAQ$0.3353
Market Cap
$13.09M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
295 of 924
Rank in Industry
169 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ATHA Insider Trading Activity
ATHA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $100,051 | 2 | 17 |
Sells | $39,229 | 10 | 83 |
Related Transactions
| Romano Kelly A | director | 2 | $100,051 | 0 | $0 | $100,051 |
| Gengos Andrew | CFO and Chief Business Officer | 0 | $0 | 1 | $720 | $-720 |
| Lenington Rachel | COO and CDO | 0 | $0 | 1 | $1,429 | $-1,429 |
| Renninger Robert | VP of Finance | 0 | $0 | 1 | $1,619 | $-1,619 |
| San Martin Javier | CHIEF MEDICAL OFFICER | 0 | $0 | 1 | $6,083 | $-6,083 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $6,211 | $-6,211 |
| Worthington Mark | GENERAL COUNSEL | 0 | $0 | 2 | $6,211 | $-6,211 |
| Litton Mark James | President and CEO | 0 | $0 | 2 | $16,956 | $-16,956 |
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Insider Activity of Athira Pharma, Inc.
Over the last 12 months, insiders at Athira Pharma, Inc. have bought $100,051 and sold $39,229 worth of Athira Pharma, Inc. stock.
On average, over the past 5 years, insiders at Athira Pharma, Inc. have bought $28.64M and sold $47,383 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Romano Kelly A (director) — $100,051.
The last purchase of 27,400 shares for transaction amount of $66,179 was made by Romano Kelly A (director) on 2024‑06‑24.
List of Insider Buy and Sell Transactions, Athira Pharma, Inc.
| 2025-01-02 | Sale | Litton Mark James | President and CEO | 25,107 0.0663% | $0.56 | $14,108 | -12.93% | |
| 2025-01-02 | Sale | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 8,510 0.0225% | $0.56 | $4,782 | -12.93% | |
| 2025-01-02 | Sale | Renninger Robert | VP of Finance | 2,881 0.0076% | $0.56 | $1,619 | -12.93% | |
| 2025-01-02 | Sale | Worthington Mark | General Counsel and CCO | 8,510 0.0225% | $0.56 | $4,782 | -12.93% | |
| 2025-01-02 | Sale | San Martin Javier | CHIEF MEDICAL OFFICER | 10,826 0.0286% | $0.56 | $6,083 | -12.93% | |
| 2024-09-05 | Sale | Litton Mark James | President and CEO | 5,032 0.0132% | $0.57 | $2,848 | -8.55% | |
| 2024-09-05 | Sale | Gengos Andrew | CFO and Chief Business Officer | 1,272 0.0033% | $0.57 | $720 | -8.55% | |
| 2024-09-05 | Sale | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 2,525 0.0066% | $0.57 | $1,429 | -8.55% | |
| 2024-09-05 | Sale | Worthington Mark | GENERAL COUNSEL | 2,525 0.0066% | $0.57 | $1,429 | -8.55% | |
| 2024-09-05 | Sale | Lenington Rachel | COO and CDO | 2,525 0.0066% | $0.57 | $1,429 | -8.55% | |
| 2024-06-24 | Romano Kelly A | director | 27,400 0.0729% | $2.42 | $66,179 | -76.58% | ||
| 2024-06-21 | Romano Kelly A | director | 15,000 0.0347% | $2.26 | $33,872 | -76.13% | ||
| 2024-01-05 | Sale | Litton Mark James | Chief Executive Officer | 4,820 0.0129% | $2.91 | $14,026 | -12.54% | |
| 2024-01-05 | Sale | Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | 1,208 0.0032% | $2.91 | $3,515 | -12.54% | |
| 2024-01-05 | Sale | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 2,412 0.0065% | $2.91 | $7,019 | -12.54% | |
| 2024-01-05 | Sale | Worthington Mark | General Counsel | 2,412 0.0065% | $2.91 | $7,019 | -12.54% | |
| 2024-01-05 | Sale | Lenington Rachel | Chief Operating Officer | 2,412 0.0065% | $2.91 | $7,019 | -12.54% | |
| 2023-12-29 | PERCEPTIVE ADVISORS LLC | 163,954 0.4272% | $2.38 | $390,211 | +3.70% | |||
| 2023-12-28 | PERCEPTIVE ADVISORS LLC | 409,598 1.0852% | $2.44 | $999,419 | +2.44% | |||
| 2023-12-27 | PERCEPTIVE ADVISORS LLC | 32,134 0.0833% | $2.28 | $73,266 | +9.09% |
Total: 43
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Litton Mark James | President and CEO | 242591 0.6214% | $81,340.76 | 0 | 4 | |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 130761 0.3349% | $43,844.16 | 0 | 5 | |
| Gengos Andrew | CFO and Chief Business Officer | 97532 0.2498% | $32,702.48 | 3 | 3 | <0.0001% |
| Renninger Robert | VP of Finance | 89724 0.2298% | $30,084.46 | 0 | 1 | |
| Worthington Mark | General Counsel and CCO | 83735 0.2145% | $28,076.35 | 0 | 4 | |
| Romano Kelly A | director | 80715 0.2067% | $27,063.74 | 4 | 0 | <0.0001% |
| San Martin Javier | CHIEF MEDICAL OFFICER | 35841 0.0918% | $12,017.49 | 0 | 1 | |
| Lenington Rachel | COO and CDO | 20870 0.0535% | $6,997.71 | 0 | 3 | |
| PERCEPTIVE ADVISORS LLC | 5402964 13.8387% | $1.81M | 5 | 0 | <0.0001% | |
| EDELMAN JOSEPH | 3695916 9.4664% | $1.24M | 2 | 0 | +8.83% | |
| RTW INVESTMENTS, LP | 10 percent owner | 2668913 6.8359% | $894,886.53 | 1 | 0 | +9% |
| MILESON GLENNA | Chief Financial Officer | 159930 0.4096% | $53,624.53 | 1 | 1 | <0.0001% |
| MOEBIUS HANS | Chief Medical Officer | 65836 0.1686% | $22,074.81 | 2 | 0 | +2.03% |
| PICKERING GRANT | director | 25783 0.066% | $8,645.04 | 2 | 0 | +12.56% |
| JOHNSON JAMES A | director | 5000 0.0128% | $1,676.50 | 1 | 0 | +14.35% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,253,997 | 122 | -53.40% | $11.34M | |
$1,724,269 | 63 | -16.36% | $12.25M | |
$383,884 | 32 | -25.10% | $12.65M | |
$4,368,362 | 28 | -22.35% | $14.54M | |
$29,469,413 | 18 | 30.38% | $13.04M | |
$86,569,038 | 18 | -12.64% | $11.26M | |
Athira Pharma, Inc. (ATHA) | $114,371,781 | 18 | -1.31% | $13.09M |
$112,810,270 | 18 | -1.20% | $13.23M | |
$490,284 | 15 | -19.03% | $11.37M | |
$122,973 | 15 | -26.96% | $14.53M | |
$941,975 | 12 | -10.74% | $11.92M | |
$38,247,728 | 10 | -10.97% | $13.84M | |
$36,538,405 | 10 | -21.99% | $14.11M | |
$11,777,042 | 10 | -11.94% | $12.89M | |
$189,648 | 9 | -52.20% | $14.86M | |
$2,891,537 | 8 | -39.31% | $13.42M | |
$31,190 | 2 | -14.18% | $14.74M | |
$245,940 | 2 | 31.12% | $14.24M | |
$19,863 | 1 | 144.27% | $11.28M |
ATHA Institutional Investors: Active Positions
| Increased Positions | 13 | +16.05% | 3M | +21.48% |
| Decreased Positions | 29 | -35.8% | 2M | -10.24% |
| New Positions | 7 | New | 3M | New |
| Sold Out Positions | 9 | Sold Out | 795,639 | Sold Out |
| Total Postitions | 65 | -19.75% | 18M | +11.24% |
ATHA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Perceptive Advisors Llc | $2,221.00 | 13.85% | 5.4M | 0 | 0% | 2024-12-31 |
| Bml Capital Management, Llc | $1,141.00 | 7.12% | 2.78M | +3M | New | 2024-12-31 |
| Vanguard Group Inc | $640.00 | 3.99% | 1.56M | -56,412 | -3.5% | 2024-12-31 |
| Propel Bio Management, Llc | $614.00 | 3.83% | 1.49M | 0 | 0% | 2024-12-31 |
| Simplify Asset Management Inc. | $614.00 | 3.83% | 1.49M | 0 | 0% | 2024-12-31 |
| Tang Capital Management Llc | $247.00 | 1.54% | 600,000 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $189.00 | 1.18% | 458,765 | -76,778 | -14.34% | 2024-12-31 |
| Acadian Asset Management Llc | $179.00 | 1.11% | 434,492 | -42,010 | -8.82% | 2024-12-31 |
| Bank Of America Corp /De/ | $171.00 | 1.07% | 416,143 | -12,635 | -2.95% | 2024-12-31 |
| Pathstone Holdings, Llc | $153.00 | 0.95% | 372,196 | -119,930 | -24.37% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.